Bolt is a pre-seed venture firm investing where the digital and physical world intersect. Bolt invests early and with conviction, leading or co-leading the first round of financing in over 90% of our portfolio companies.  Bolt has invested in over 70 companies and is currently investing from our $70M Fund.

Bolt

Social Starts is a venture capital firm with a data-driven approach to investing in moment-of-inception and Series A financing rounds. The firm prefers to invest in early-stage companies operating in the technology, health tech, internet, and mobile tech sectors.

Social Starts

Life Science Angels, Inc. (LSA) is the premier angel investment group focused solely on healthcare investing, including medical devices, diagnostics, pharmaceuticals, biotechnology, and digital health.

Life Science Angels

Joyance Partners invests in companies that, through science and tech, cultivate joy to improve how we live, focusing on the health and consumer sectors from Pre-Seed to Series A.

Joyance Partners

OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investments series of venture capital funds and a family of public equity investment funds.

OrbiMed

The S.H.I.P. team brings more than 50 years of cumulative healthcare experience in investing and operational roles. We have invested globally in more than 60 companies through multiple market cycles. We worked together on a number of healthcare investments over the last 12 years prior to forming S.H.I.P.  We bring a unique set of investing experiences from one of the largest strategic healthcare funds JJDC, which maintains a portfolio of over $1B and annually invests more than $200 million in medical devices, biotech, and consumer health, and private venture investing experiences at Synergy Life Science Partners, a top quartile performing venture capital fund. The S.H.I.P. team has been involved in some of the premium healthcare companies bringing novel technologies to market.

Treo Ventures

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. They are committed to improving the lives of patients and families who deal with chronic disease, and they support the healthcare professionals who dedicate their lives to helping them. LivaNova is also dedicated to the highest standards, and they operate at the topmost level of business ethics and compliance. As a strong, market-leading medical technology and solutions company, they understand the importance of bringing both clinical and economic value to their customers. LivaNova offers a diverse product portfolio with a differentiated pipeline. Their global reach is broad with a presence in more than 100 countries and approximately 4,000 employees.

LivaNova

Sectoral Asset Management Inc. is an industry-leading specialist in managing global investment portfolios in the healthcare sector.  Sectoral maintains offices in Montreal and Geneva and is a proud member of the State Street Global Alliance. They currently manage approximately US $4.0 billion in assets.

Sectoral Asset Management

Asahi Kasei Corporation provides solutions based in chemistry and materials science to a range of markets, including fibers, chemicals, consumer products, housing, construction, electronics, and health care primarily in Japan. Segments Chemicals The Chemicals Segment offers organic and inorganic industrial chemicals, synthetic resin, synthetic rubber, high-compound fertilizer, coating materials, latex, pharmaceutical and food additives, explosives, photopolymers and platemaking systems, separation and ion-exchange membranes, systems, and equipment. The company produces, processes, and sells chemicals and derivative products, such as ammonia, nitric acid, caustic soda, acrylonitrile, styrene monomer, methyl methacrylate (MMA) monomer, PMMA resin, high-compound fertilizers, and adipic acid; polymer products, such as Suntec polyethylene (PE), Stylac-AS (styrene-acrylonitrile), Stylac-ABS (acrylonitrile-butadiene-styrene), synthetic rubber, Tenac polyacetal, Xyron modified polyphenylene ether (mPPE), and Leona nylon 66 polymer and filament); and specialty products, such as coating materials, latex, Ceolus microcrystalline cellulose, explosives, explosion-bonded metal clad, APR photosensitive resin and printing plate making systems, Microza UF and MF membranes and systems, Hipore microporous membrane, ion-exchange membranes and electrolysis systems, Saran Wrap cling film, Ziploc storage bags, and plastic films, sheets, and foams.

Asahi Kasei

At ResMed we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries.

ResMed

Angelini Ventures

Noctrix Health

Noctrix Health is an early-stage medical device company that focuses on developing a revolutionary therapy for a chronic illness.

<div>Noctrix Health is a developer of a prescription-grade non-pharmaceutical therapeutic for the treatment of moderate-to-severe Restless Leg Syndrome (RLS) in patients who are resistant to pharmaceutical treatments. The therapeutic called the NTX100 Nidra Tonic Motor Activation (TOMAC) System consists of two bands that are worn on the patient's lower legs that function as neurostimulation devices. The device electrically activates peroneal nerves bilaterally to produce muscle activation compatible with sleep and suppressing symptoms of RLS. The company has carried out studies on the therapeutic to clinically validate its treatment capabilities.</div>

A new industry proving that digital connectivity and mental health can co-exist.

Digital Wellness

Noctrix Health is a medical device company that has developed the NTX100 Tonic Motor Activation (TOMAC) System, a non-pharmacologic, wearable treatment for adults with moderate to severe, drug-refractory restless legs syndrome (RLS). The system, which received De Novo authorization from the US Food and Drug Administration (FDA) in April 2023, consists of a pair of devices worn on the lower legs that electrically activate the peroneal nerves bilaterally. This produces tonic, sustained muscle activation compatible with sleep, thereby reducing RLS symptoms and improving sleep quality.

FDA Grants De Novo Status for Wearable System to Treat RLS

Noctrix Health announces publication of landmark results from randomized clinical trial and long-term extension study of its revolutionary Tonic Motor Activation (TOMAC) therapy for Restless Legs Synd

Noctrix Health Closes $40M Series C Round to Commercialize Wearable for RLS

MCRA Helps Noctrix Secure Marketing Authorization for RLS Therapy Device

Noctrix Health secures funding to advance Nidra TOMAC therapy

Noctrix Health announces successful randomized controlled trial (RCT) outcomes and FDA Marketing Authorization for its Breakthrough Tonic Motor Activation (TOMAC) Restless Legs Syndrome (RLS) Therapy

Noctrix Health Raises $40M in Series C Financing

NOCTRIX HEALTH SECURES $40 MILLION SERIES C FINANCING TO COMMERCIALIZE NOVEL DEVICE TREATMENT FOR RESTLESS LEGS SYNDROME (RLS)

term extension study of its revolutionary Tonic Motor Activation (TOMAC) therapy for Restless Legs Syndrome (RLS) in Sleep

Update on TOMAC device (new treatment... - Restless Legs Syn...

FDA grants De Novo request for restless legs syndrome therapy

Transforming neurological care with innovation

Neurostimulation Tech

Noctrix Health, Inc.’s Post

<div>
 
 Noctrix Health is a developer of a prescription-grade non-pharmaceutical therapeutic for the treatment of moderate-to-severe Restless Leg Syndrome (RLS) in patients who are resistant to pharmaceutical treatments. The therapeutic called the NTX100 Nidra Tonic Motor Activation (TOMAC) System consists of two bands that are worn on the patient's lower legs that function as neurostimulation devices. The device electrically activates peroneal nerves bilaterally to produce muscle activation compatible with sleep and suppressing symptoms of RLS. The company has carried out studies on the therapeutic to clinically validate its treatment capabilities. 
 
 
 In April 2023, Noctrix Health was granted its De Novo request from the FDA, allowing it to begin marketing its Nidra TOMAC system. Previously, in June 2020, Noctrix was granted FDA Breakthrough Device Designation. 
 
 
 
 
 Funding and financials
 
 
 
 
 
 In January 2024, the company raised USD 40 million in a Series C funding round led by Sectoral Asset Management, along with participation from new and existing investors. The raised funds were set aside for furthering the advancement of the Nidra TOMAC device, along with supporting the launch of the therapeutic in the US market. 
 
</div>

Headspace is a digital wellness company that delivers meditation programs through a smartphone app. The company was founded by Andy Puddicombe, a former Buddhist monk, and Richard Pierson, a marketing and brand development professional. In addition to meditation, Headspace offers stress management programs, mindfulness activities, and sleep therapy solutions. Headspace also operates a business-to-business (B2B) focused “Headspace for Work” program with around 1,600 corporate customers as of January 2021, which has seen around 3x growth during 2020. Further, the company operates “Headspace for Health,” a program that develops US Food and Drug Administration (FDA) approved meditation tools to treat chronic diseases.As of January 2023, the company has over 100 million users across 190 countries, with its brands “Headspace for Work” and “Ginger” being used by over 4,000 enterprises including Starbucks, Adobe, Delta Air Lines, Mattel, and Paramount. The company also partners with a health plans, such as Cigna, to provide its services.In January 2022, the company <a href="https://sp-edge.com/updates/7781">acquired Sayana </a>, an AI-powered mental health provider which helps employees manage stress and anxiety, improve sleep and increase productivity. The acquisition was carried out to expand Headspace's services to provide personalized self-care to its users.In June 2022, the company launched a <a href="https://sp-edge.com/updates/11145">new training program for senior leaders </a>and managers to support mental well-being in the workplace.In September 2022, the company <a href="https://sp-edge.com/updates/12918">acquired fellow mindfulness platform Shine </a>for an undisclosed amount. The acquisition enhanced Headspace Health’s offerings by supporting inclusiveness and diversity while also growing Headspace’s member base. Select content from Shine was earmarked to be added to Headspace Health’s content library.In November 2022, the company launched a new platform that combines its product offerings with mental health platform Ginger’s <a href="https://sp-edge.com/updates/5119">an entity it merged with in August 2021 </a>. The platform combines Headspace Health’s meditation and mindfulness services with Ginger’s on-demand coaching, therapy, and psychiatry services, to offer enterprise clients an integrated solution for supporting their employees.In January 2023, the company <a href="https://sp-edge.com/updates/16052">expanded its geographical reach </a>to offer coaching, therapy, and employee assistance-related services to UK headquartered enterprise clients. The company stated it plans on continuing this international expansion into other countries throughout 2023 but did not mentioned specifics.In April 2024, Headspace <a href="https://sp-edge.com/updates/28767">introduced a new mental health coaching service </a>that offered one-on-one support in tackling a wide range of life challenges. The service was available to its direct-to-consumer subscribers at a rate of USD 99.99 per month. The company claimed the experts had been trained to help individuals set realistic goals, initiate new habits, and motivate change while providing them full responsibility for their achievement.In July 2024, the company <a href="https://sp-edge.com/updates/31551">announced that Tom Pickett will be its new CEO</a> and member of the company's board of directors, effective August 12, 2024.Key customers and partnershipsIn June 2023, the company <a href="https://sp-edge.com/updates/19771">extended its partnership with with employee benefit management platform provider Virgin Pulse </a>to integrate its platform with Virgin Pulse’s platform. This integration enables employees enrolled in Virgin Pulse’s health benefit offerings to access the full suite of Headspace’s offerings as a part of Virgin Pulse’s Homebase for Health platform.In March 2024, Headspace <a href="https://sp-edge.com/updates/27330">partnered with Meta </a>to launch "Headspace XR," available for an upfront fee of USD 30. Headspace XR provides guided mindfulness and meditation exercises led by the same instructors familiar to regular Headspace users. The exercises cover activities such as breathing techniques, body scans, and mood tracking. Additionally, it incorporates a social element, including interactive metaverse-style gaming in vivid environments.In June 2024, Headspace <a href="https://sp-edge.com/updates/30378">partnered with Uwill</a>, a mental health platform for colleges and students, to integrate Headspace's wellness services into Uwill's existing portal. The collaborative effort will allow Uwill's Urise program to incorporate Headspace's services, primarily meditation, yoga, and mindfulness offerings.Most recently, in August 2024, Headspace <a href="https://sp-edge.com/updates/21452">partnered with Castell</a>, a value-based care (VBC) subsidiary of Intermountain Healthcare, to offer mental health services to members of select insurance plans in Utah. The partnership aimed to improve health outcomes by providing personalized mental healthcare to members. Through the partnership, Castell began refering eligible members to Headspace for behavioral health coaching and therapy, giving them access to a team of coaches and licensed therapists through an outcomes-based payment model.

Headspace

<div>
 
 Calm is a digital wellness company which offers guided meditations to make people happy as well as mindfulness and sleep programs through a smartphone app. Its audio content is designed to strengthen mental fitness and address mental health challenges such as stress, anxiety, insomnia, and depression. The company started out as a website in 2011 where users were trained to stare at a screen and listen to waves on a beach for two minutes without touching their mouse. In February 2013, more content was added and the company launched a mobile app. Calm was named by Apple as the 2017 iPhone App of the Year and received Editors' Choice certification by Google in 2018. Calm offers content in English, Spanish, French, and German and operates Calm Business, a business-to-business (B2B) covering over 10 million employees as of March 2022. 
 
 
 
 
 Calm gained significant traction in 2020 during the Covid-19 lockdowns. It became the most downloaded digital wellness app during April 2020 with 3.9 million downloads worldwide, including 1.6 million downloads in the US. Kaiser Permanente, a large managed care service provider, provided Calm free for its 12.4 million members in May 2019. Calm also partnered with CNN on the 2020 US presidential election day to play the sound of rain hitting leaves on air, a marketing effort that went viral on social media.
 
 
 As of December 2020, Calm has reported over 100 million app downloads (compared with over 40 million in early 2019 and over 80 million as of May 2020) and was valued at USD 2 billion. 
 
 
 In October 2022, the company 
 <a href="https://sp-edge.com/updates/13853">
 launched a new clinical mental health offering
 </a>
 called &ldquo;Calm Health,&rdquo; marking its expansion into the mental health space. The new solution provides condition-specific programs designed to bridge mental and physical care and includes tools for communication with providers and medication tracking. This solution was created for the company by Ripple Health, which was 
 <a href="https://sp-edge.com/updates/8246">
 acquired by Calm
 </a>
 in February 2022. 
 
 
 Key customers and partnerships
 
 
 As of December 2022, the company has partnered with over 20 brands to collaborate and provide its services through sales partnerships. These brands include Xbox, Amazon, YouTube, Adidas, Fitbit, and American Express. 
 
 
 Funding and financials
 
 
 In December 2020, Calm raised USD 75 million in a series C funding round led by Lightspeed Venture Partners doubling it&rsquo;s valuation to USD 2.0 billion. Calm planned to use the funding to expand operations globally and broaden its B2B offerings.
 
</div>

Calm

<div>
 
 Simple Habit is a guided meditation service provider, which offers bite sized, five-minute long meditation sessions through an app targeting people with busy schedules. The company also offers mindfulness, sleep, and wellness programs. As of November 2020, Simple Habit offered over 2,000 sessions designed to help users sleep, reduce anxiety, and get over relationship issues. The content is organized by occasion, such as commuting, going to sleep or preparing for a meeting. 
 
 
 In June 2022 the company launched its Sleep Habit app, a virtual sleep clinic that helps users improve the quality of their sleep. The app uses clinically validated approaches to improve sleep quality and treat issues such as insomnia via methods such as cognitive behavioral therapy. 
 
 
 As of September 2022, Simple Habit claims to have a 7 million users between both of its apps. 
 
 
 
 
 In November 2018, Simple Habit raised USD 10 million in a Series A round led by Foundation Capital, bringing the company’s total funding to USD 12.6 million. The company used the funds to expand its library of guided meditation sessions and to add audio content led by therapists and executive coaches. As of late 2018, the app was reported to sign up as many as 30,000 new users per week. As of November 2020, Simple Habit reported having helped helped over five million people reduce burnout through its app’s services.
 
</div>

Simple Habit

<div>
 
 Insight Timer is a company which offers guided meditation, yoga, and sleep programs through a smartphone app. It also offers free interactive live sessions with teachers, performers, and therapists through the app and web. The company’s business-to-business (B2B) offering, “Circles for teams”, targets enterprise customers to help bring employees together to practice group meditations, chat with each other, and recommend content. In October 2020, Insight Timer began offering free, daily live yoga classes from instructors based on a pay-what-you-can model.
 
 
 
 
 As of October 2020, Insight Timer featured around 8,000 meditation teachers providing over 70,000 free tracks on guided meditations in 50 languages as well as 5,000 music tracks. The company has also claimed that it ranks first in the US among meditation apps in terms of the time spent by users with Insight Timer boasting 63% of the time spent on meditation apps as of 2018.
 
 
 
 
 The majority of the content is available for free, and users can sign up for a premium version at a price of USD 9.99 per month or USD 59.99 per year. Premium users get access to content such as Insight courses and the ability to download content.
 
 
 
 
 In January 2020, the company raised USD 27.4 million. As of November 2020, the monthly operating cost of the company is reported to be around USD 1 million and Insight Timer has failed to break even as of the end of 2020. The founder attributes the significant growth of the company to its free content and has advocated against moving too much of its content behind the premium subscription paywall. As of November 2020, the app had a 16% 30-day retention rate, more than double the average retention rate of 7.7% for top 100 apps in Apple’s App Store. As of November 2021, the company has 19 million users. 
 
</div>

Insight Timer

<div>
 
 Big Sky Health is the developer of the Oak Meditation breathing app. Oak Meditation offers guided and unguided meditations, sleep meditations, meditation timers, yogic exercises for breathing, animated instructions, and music tracks. The company is headed by Mike Maser, an entrepreneur who was diagnosed with stage IV cancer. Most of the companies services are offered free of charge with in-app purchases ranging from USD 5.99 to USD 38.99.
 
 
 
 
 In addition to Oak meditation, Big Sky also offers a fasting app called Zero and an alcohol moderation app called Less. In May 2020, Big Sky raised USD 8 million in Series A funding in a round led by Greycroft with participation from existing investors True Ventures and Trinity Ventures, bringing the company’s total funding to USD 12.2 million. Big Sky Health expects to use the funds to expand its staff and boost customer acquisition.
 
</div>

Big Sky Health

Apps that provide relaxation, stress reduction and non-therapeutic mental health support via meditation-related techniques.

These apps aim to increase users’ body and brain functions including memory and attention to detail with microlearning, gamification, and journaling techniques.

Helps users analyze and address sleep disorders with wearable tech, music and sound therapy, and storytelling.

Apps that provide virtual training programs, track workouts, and provide guides for nutrition.

Some digital wellness providers provider VR/AR experiences for meditations

Some companies offer personalized care/meditation plans, workout regimens, or treatments for sleep disorders

Offers app-based platforms that improve health and wellness

Noctrix Health is a medical device company that has developed the NTX100 Tonic Motor Activation (TOMAC) System, a non-pharmacologic, wearable treatment for adults with moderate to severe, drug-refractory restless legs syndrome (RLS). The system, which received De Novo authorization from the US Food and Drug Administration (FDA) in April 2023, consists of a pair of devices worn on the lower legs that electrically activate the peroneal nerves bilaterally. This produces tonic, sustained muscle activation compatible with sleep, thereby reducing RLS symptoms and improving sleep quality.
The TOMAC therapy, also known as Nidra, is the first and only FDA-approved treatment specifically designed for patients with moderate to severe RLS who do not respond to medications. Its efficacy and safety have been demonstrated in clinical studies, including the RESTFUL study, a multi-center, randomized, sham-controlled trial involving 133 participants. All seven efficacy outcomes in this study met statistical significance, with the therapy proving well-tolerated and free of significant adverse events.
A subsequent 24-week extension study further validated the long-term benefits of TOMAC therapy, with patients experiencing an average reduction of 11.3 points on the International RLS Rating Scale (IRLS) and a mean responder rate (CGI-I) of 72.7% at week 24. Notably, long-term treatment led to a substantial reduction in the frequency of RLS symptoms, from 5.9 nights to 3.2 days per week, and a mean reduction of 17.2 points on the MOS-II sleep scale.
In January 2024, Noctrix Health secured USD 40 million in Series C financing to support the commercial launch of Nidra in the US market. The funding round was led by Sectoral Asset Management, with participation from Angelini Ventures, ResMed, Asahi Kasei Corporation, OrbiMed, and Treo Ventures.

Aleva Neurotherapeutics is a medical device company specializing in deep brain stimulation (DBS) systems for treating neurological disorders such as Parkinson's disease and essential tremor. Based in Lausanne, Switzerland, the company was founded as a spin-off from the Swiss Federal Institute of Technology. Aleva pioneered the development of directional DBS leads with its flagship product, the directSTIM DBS system. This technology aims to deliver more precise electrical stimulation to targeted areas of the brain, potentially improving therapeutic benefits and reducing side effects compared to traditional omnidirectional DBS leads.
The directSTIM system features a novel 12-electrode lead design based on microelectromechanical systems (MEMS) technology. This allows for smoother electrode surfaces and customized shapes optimized for implantation in the brain. The system also incorporates 24 independent current sources, enabling greater flexibility in programming and personalizing stimulation patterns to each patient's unique needs. In May 2024, Aleva received CE marking for the directSTIM system, allowing its commercial launch in Europe.
Aleva's expertise in DBS technology is reflected in its robust intellectual property portfolio, comprising 13 patent families and 90 granted patents related to DBS for neurological and psychiatric disorders. The company aims to transform DBS therapy by combining advanced technologies with shared clinical data to improve surgical experiences and patient outcomes.

Aleva Neurotherapeutics

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The company has developed Deep Transcranial Magnetic Stimulation (Deep TMS), a proprietary technology that uses magnetic pulses through a patented H-coil helmet to stimulate deeper and broader brain regions associated with various conditions.
Deep TMS received FDA clearance for treating major depressive disorder (MDD) in 2013, making BrainsWay the first and only TMS company with clinical evidence demonstrating efficacy for this indication. In 2018, the technology obtained FDA clearance for treating obsessive-compulsive disorder (OCD), and in 2021, it was cleared as an aid for short-term smoking cessation.
The Deep TMS treatment is administered through a series of daily sessions over four to six weeks, with each session lasting around 20 minutes. It has been investigated in over 30 randomized clinical trials worldwide, demonstrating its safety and effectiveness. As of April 2021, BrainsWay announced that 100,000 patients have been treated globally with Deep TMS.
In addition to the FDA-cleared indications, BrainsWay is conducting ongoing or planned clinical trials exploring Deep TMS for various psychiatric, neurological, and addiction disorders. The company's commitment to clinical research and building upon its substantial body of evidence positions it as a leader in advancing neuroscience through non-invasive solutions.

Brainsway

Cala Health is a bioelectronic medicine company that has developed the Cala kIQ system, a wearable neuromodulation device that delivers transcutaneous afferent patterned stimulation (TAPS) therapy for the relief of hand tremors in adults with essential tremor and Parkinson's disease. The Cala kIQ system comprises a stimulator, a band with integrated electrodes, and a base station. It utilizes a calibrated TAPS output pattern adjusted to match the patient's unique tremor frequency, providing personalized stimulation to the median and radial nerves of the wrist.
The Cala kIQ system received 510k clearance from the US Food and Drug Administration (FDA) in November 2022 and was launched for human use in June 2023. The device offers treatment sessions of 40 minutes, with a wristband life of 90 days and a shelf life of three months. Patients can review their therapy session results through the MyCala.com patient portal and share them with healthcare providers.
Cala Health has reported positive clinical data demonstrating the effectiveness of TAPS therapy in reducing tremors and improving activities of daily living for essential tremor patients. The company has secured reimbursement and coding from various commercial and government payors, including Medicare, to improve patient access to the therapy.

Cala Health

Cardionomic is a medical device company based in Minneapolis that has developed the Cardiac Pulmonary Nerve Stimulation (CPNS) System, an investigational device designed to treat patients suffering from acute decompensated heart failure (ADHF). The CPNS System consists of a stimulation console and an endovascular catheter that delivers targeted stimulation to the cardiac plexus located in the right pulmonary artery.
The company's approach is founded on the principle that stimulating the autonomic nerves improves a patient's clinical condition by triggering a rebalancing of the autonomic system, shifting it from an imbalanced state into a cycle that enhances the patient's condition even after the therapy is completed. The CPNS System has demonstrated the ability to increase cardiac contractility without significantly affecting heart rate in heart failure patients with reduced ejection fraction.
In January 2024, Cardionomic announced the completion of enrollment in the STIM-ADHF and STOP-ADHF pilot studies, which evaluated the safety and performance of the CPNS System in treating ADHF patients. A total of 35 patients were treated across seven countries. Preliminary results suggest that the CPNS therapy may address the unmet need for more effective treatment options for hospitalized heart failure patients. The pooled data from these studies is planned for publication in early 2024.
The CPNS System leverages engineered electrode surfaces from Pulse Technologies, Inc. to deliver durable electrochemical performance for the neural and cardiac interfacing applications.

Cardionomic

Charco Neurotech was founded in 2019 by Lucy Jung, an industrial designer who was inspired to develop assistive devices for Parkinson's after her own experience as a patient. The CUE1 is a small plastic disc with an electric motor that vibrates at a high frequency in a specialized pattern. This pattern, proven through research, can disrupt the overactive brainwaves that cause Parkinson's symptoms, allowing for improved movement.
The CUE1 attaches to the user's sternum using medical adhesive and is relatively inexpensive compared to other treatments like deep brain stimulation implants. Over 2,000 people in the UK are currently using the CUE1, with a waiting list of almost 20,000 across 120 countries as of March 2024. Charco has raised over USD 10 million in funding and grants, employing around 38 people across the UK, South Korea, and the US.
The device is accompanied by a smartphone app that enables users to personalize the stimulation settings and track their symptoms. Charco aims to obtain regulatory approvals for the CUE1 to be prescribed through healthcare systems like the NHS. In April 2023, Addenbrooke's Hospital in Cambridge became the first hospital to trial the device on inpatients with Parkinson's.
Key customers and partnerships
As of August 2023, over 1,700 people are benefiting from the CUE1 in the UK, and there is a waiting list of over 17,000 people worldwide. Charco has partnered with Dr. Alistair Mackett, a consultant geriatrician at Cambridge University Hospitals, to conduct trials and research on the device's effectiveness.

Charco Neurotech

Companies that offer solutions for pain management, neuropathies, and related disorders and migraines.

Companies that provide solutions for Parkinson's disease, epilepsy, and speech and movement disorders.

Companies that offer treatments for depression, Alzheimer's, and other mental health-related disorders.

Companies that offer solutions for heart-related medical issues such as acute decompensated heart failure and high blood pressure.

Companies that offer solutions for urinary or fecal incontinence, autoimmune diseases and other functional impairments

Companies that offer solutions for hearing or vision impairment, sleep-related conditions, and other disorders, including obesity treatments.

Noctrix Health

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless